$73.40
0.47% yesterday
NYSE, Jun 25, 10:14 pm CET
ISIN
US4050241003
Symbol
HAE

Haemonetics Corporation Target price 2025 - Analyst rating & recommendation

Haemonetics Corporation Classifications & Recommendation:

Buy
91%
Hold
9%

Haemonetics Corporation Price Target

Target Price $93.00
Price $73.40
Potential
Number of Estimates 10
10 Analysts have issued a price target Haemonetics Corporation 2026 . The average Haemonetics Corporation target price is $93.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend Haemonetics Corporation to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Haemonetics Corporation stock has an average upside potential 2026 of . Most analysts recommend the Haemonetics Corporation stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion $ 1.36 1.30
3.95% 4.34%
EBITDA Margin 21.57% 33.22%
15.12% 54.02%
Net Margin 12.32% 12.92%
37.21% 4.85%

10 Analysts have issued a sales forecast Haemonetics Corporation 2026 . The average Haemonetics Corporation sales estimate is

$1.3b
Unlock
. This is
4.34% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.3b 3.51%
Unlock
, the lowest is
$1.3b 5.13%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $1.4b 3.95%
2026
$1.3b 4.34%
Unlock
2027
$1.4b 7.95%
Unlock
2028
$1.5b 9.81%
Unlock
2029
$1.6b 6.07%
Unlock
2030
$1.8b 7.40%
Unlock

6 Analysts have issued an Haemonetics Corporation EBITDA forecast 2026. The average Haemonetics Corporation EBITDA estimate is

$432m
Unlock
. This is
52.33% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$463m 63.15%
Unlock
, the lowest is
$405m 42.50%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $294m 19.67%
2026
$432m 47.33%
Unlock
2027
$469m 8.46%
Unlock
2028
$491m 4.61%
Unlock

EBITDA Margin

2025 21.57% 15.12%
2026
33.22% 54.02%
Unlock
2027
33.38% 0.48%
Unlock
2028
31.80% 4.73%
Unlock

5 Haemonetics Corporation Analysts have issued a net profit forecast 2026. The average Haemonetics Corporation net profit estimate is

$168m
Unlock
. This is
0.32% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$181m 7.91%
Unlock
, the lowest is
$154m 7.98%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $168m 42.63%
2026
$168m 0.32%
Unlock
2027
$210m 24.88%
Unlock
2028
$239m 13.63%
Unlock
2029
$274m 14.95%
Unlock
2030
$312m 13.53%
Unlock

Net Margin

2025 12.32% 37.21%
2026
12.92% 4.85%
Unlock
2027
14.95% 15.71%
Unlock
2028
15.47% 3.48%
Unlock
2029
16.76% 8.34%
Unlock
2030
17.72% 5.73%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share $ 3.31 3.49
44.54% 5.44%
P/E 21.04
EV/Sales 3.41

5 Analysts have issued a Haemonetics Corporation forecast for earnings per share. The average Haemonetics Corporation EPS is

$3.49
Unlock
. This is
3.25% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$3.75 10.95%
Unlock
, the lowest is
$3.20 5.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $3.31 44.54%
2026
$3.49 5.44%
Unlock
2027
$4.36 24.93%
Unlock
2028
$4.95 13.53%
Unlock
2029
$5.69 14.95%
Unlock
2030
$6.46 13.53%
Unlock

P/E ratio

Current 21.72 41.88%
2026
21.04 3.11%
Unlock
2027
16.85 19.91%
Unlock
2028
14.83 11.99%
Unlock
2029
12.90 13.01%
Unlock
2030
11.36 11.94%
Unlock

Based on analysts' sales estimates for 2026, the Haemonetics Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.27 13.72%
2026
3.41 4.40%
Unlock
2027
3.16 7.37%
Unlock
2028
2.88 8.93%
Unlock
2029
2.72 5.72%
Unlock
2030
2.53 6.90%
Unlock

P/S ratio

Current 2.59 21.69%
2026
2.71 4.54%
Unlock
2027
2.51 7.37%
Unlock
2028
2.28 8.94%
Unlock
2029
2.15 5.72%
Unlock
2030
2.01 6.90%
Unlock

Current Haemonetics Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities
Locked
Locked
Locked May 20 2025
Raymond James
Locked
Locked
Locked May 09 2025
Needham
Locked
Locked
Locked May 08 2025
Needham
Locked
Locked
Locked Mar 18 2025
Needham
Locked
Locked
Locked Feb 07 2025
Raymond James
Locked
Locked
Locked Feb 07 2025
JMP Securities
Locked
Locked
Locked Feb 07 2025
Analyst Rating Date
Locked
JMP Securities:
Locked
Locked
May 20 2025
Locked
Raymond James:
Locked
Locked
May 09 2025
Locked
Needham:
Locked
Locked
May 08 2025
Locked
Needham:
Locked
Locked
Mar 18 2025
Locked
Needham:
Locked
Locked
Feb 07 2025
Locked
Raymond James:
Locked
Locked
Feb 07 2025
Locked
JMP Securities:
Locked
Locked
Feb 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today